Objective: To determine whether healthy males who consumed increased amounts of dietary stearic acid compared with increased dietary palmitic acid exhibited any changes in their platelet aggregability, platelet fatty acid pro®les, platelet morphology, or haemostatic factors. Design: A randomized cross-over dietary intervention. Subjects and interventions: Thirteen free-living healthy males consumed two experimental diets for 4 weeks with a 7 week washout between the two dietary periods. The diets consisted of $ 30% of energy as fat (66% of which was the treatment fat) providing $ 6.6% of energy as stearic acid (diet S) or $ 7.8% of energy as palmitic acid (diet P). On days 0 and 28 of each dietary period, blood samples were collected and anthropometric and physiological measurements were recorded. Results: Stearic acid was increased signi®cantly in platelet phospholipids on diet S (by 22%), while on diet P palmitic acid levels in platelet phospholipids also increased signi®cantly (8%). Mean platelet volume, coagulation factor FVII activity and plasma lipid concentrations were signi®cantly decreased on diet S, while platelet aggregation was signi®cantly increased on diet P. Conclusion: Results from this study indicate that stearic acid (19 gaday) in the diet has bene®cial effects on thrombogenic and atherogenic risk factors in males. The food industry might wish to consider the enrichment of foods with stearic acid in place of palmitic acid and trans fatty acids.
Introduction
The relationship between dietary fatty acids and blood cholesterol levels was reported in the late 1950s when Keys et al (1957) found that saturated fatty acids (SFA) from 12 to 18 carbon atoms were potent cholesterol-raising agents. Subsequently, it was found that the predictive equations for dietary fatty acids on plasma cholesterol levels were inadequate when cocoa butter was used (Hegsted et al, 1965; Keys et al, 1965) . This was attributed to the stearic acid in the cocoa butter. Since then, various predictive equations incorporating individual saturated fatty acid contributions to plasma cholesterol changes show stearic acid as neutral (Kris-Etherton & Mustad, 1994) .
The risk of coronary events however is not solely dependent on plasma cholesterol levels. Carefully conducted autopsy studies have demonstrated that thrombotic obstruction of the coronary artery is involved in most cases of sudden cardiac death (Davies & Thomas, 1984) . Arterial thrombosis involves clot formation based around existing plaque and arterial lesions with the ®rst step involving platelet aggregation, followed by ®brin formation through activation of the coagulation pathways. Any factor leading to increased platelet activity or up-regulation of the coagulation cascade will thus increase the risk of thrombotic events.
Early studies suggested that stearic acid was prothrombotic based on three levels of evidence. Firstly, Connor (1962) reported that stearic acid was particularly effective at shortening thrombus formation time during in vitro studies using citrated blood and sodium salts of fatty acids. Secondly, Renaud and Gautherton (1975) reported that diets rich in stearic acid were associated with increased coagulation in New Zealand rabbits. This change was speculated to result from an enhanced activity of platelet factor 3 (PF3) due to an increase in stearic acid in the platelet phospholipids. Thirdly, Renaud et al (1978) found that saturated fat and especially stearic acid were signi®cantly correlated with clotting activity and platelet aggregation in several population comparisons in man. These data alerted researchers to potentially negative effects of stearic acid on thrombotic factors and resulted in several short-term studies being conducted in humans (Tholstrup et al, 1994 (Tholstrup et al, , 1996 Schoene et al, 1992; Mutanen & Aro, 1997; Dougherty et al, 1995) . However, few of these have examined more than one measure of thrombosis tendency. Because there are often interactions involving more than one component of the haemostatic system, there is no single screening test which can be used to identify a thrombotic tendency. Therefore a range of screening tests should be adopted to detect markers known to be associated with cardiovascular risk (Giddings & Yamamoto, 1995) .
The aim of this study was to compare the thrombosis potential of diets rich in stearic acid with palmitic acid-rich diets by measuring platelet aggregation, platelet volume and other key components of the haemostatic pathways.
Methods

Subjects
Thirteen free-living healthy males were recruited following advertisement of the study throughout RMIT University. Subjects were aged 35 AE 12 y (mean AE s.d.), of normal body weight (body mass index (BMI) 26.0 AE 3.3 kgam 2 . Subjects had no known metabolic, endocrine or haematological diseases, were non-smokers, not on any form of medication and had a moderate activity level. Subjects were advised not to take any form of non-steroidal anti-in¯ammatory drugs 14 days prior to commencement and during the study. Subjects were counselled to maintain their usual intake of alcohol and to abstain from consuming alcohol 24 h prior to blood sampling. All subjects were required to give written consent to participate and were free to withdraw at any time. The study protocol was approved by the Human Research Ethics Committee of RMIT University (approval number 17a96).
Experimental design
The dietary intervention consisted of subjects consuming both a high stearic (diet S) and a high palmitic acid diet (diet P) for 4 weeks in a random crossover design, with a 7 week wash-out (habitual diet) period between the two phases. Subjects consumed the equivalent of approximately twothirds of their habitual fat intake, as the test fats, during the intervention periods.
Subjects were counselled prior to commencement of the ®rst intervention period on which foods were to be excluded from the diet (included in a detailed information booklet). Advice was provided on suitable low-fat alternatives to substitute for foods normally eaten, such as regular fat dairy products, pastries and cakes etc. Subjects were given training in recording their food intakes and completed a 7 day weighed food record of their habitual diet prior to the study. Seven day weighed food records were also obtained during each intervention period and washout phase. Dietary composition was determined using Diet 1 (Version 4, NUTTAB 95, Xyris Software Pty Ltd, Queensland, Australia) based on Composition of Foods, Australia (National Food Authority, 1995). The database was modi®ed by the inclusion of fatty acid data, for a wider variety of foods, for C12:0 to C18:0 (lauric, myristic, palmitic and stearic acids), palmitoleic acid (C16:ln-7) and oleic acid (C18:ln-9), linoleic acid (18:2n-6) and alpha linolenic acid (18:3n-3) obtained from Dr M James, University of Adelaide.
During the two intervention stages, the percentage energy derived from fat, carbohydrate and protein was kept constant for each individual, based on habitual food records. The high stearic and high palmitic acid test fats were supplied by Meadow Lea Foods (Sydney, Australia). Test fats were supplied to subjects in the form of baking and spreading margarines and incorporated into biscuits, cakes and muf®ns given as snacks and in salad rolls supplied for weekday lunches. Breakfasts, dinners and weekend lunches were left to the subjects' discretion following dietary modi®cation advice. The remaining fat intake was obtained from commercially available foods low in fat.
Test fats
The stearic acid-enriched baking margarine was produced by an interesteri®ed blend of 35% hardened canola (100% hydrogenated) and 65% Sunola 1 (a high oleic acid variety of sun¯ower seed oil), and the stearic acid-enriched spreading margarine was a blend of 30% hardened canola and 70% Sunola 1 . The palmitic acid-enriched baking margarine was produced by interesterifying a blend of 55% palm stearin, 20% palm olein and 25% Sunola 1 . The palmitic acidenriched spreading margarine was produced as a mixture of interesteri®ed palm stearine (50%) and Sunola 1 (50%). Both stearic acid and palmitic acid levels in their respective margarines were maximized within the limits of physical property characteristics conducive to normal use. The oleic acid content in the stearic acid-rich fats and biscuits was higher than for the palmitic acid-rich fats and biscuits in order for stearic acid products to be spreadable at room temperature. The fatty acid pro®le of the margarines used is shown in Table 1 .
Physiological measurements
Subjects had their weight, height and body mass index (BMI, kgam 2 ) determined, and percentage body fat measured using a bioimpedence fat analyserascale (TBF-501 Tanita Corporation, Illinois, USA). Systolic and diastolic blood pressures and pulse were also measured at each appointment on a Lumiscope Digital Auto In¯ate Blood Pressure Monitor (Lumiscope Company Inc., NJ, USA).
Blood sampling and preparation
Fasting venous blood samples ( ! 10 h) were taken from the subjects before the commencement (day 0) and at the end (day 28) of each study period by a quali®ed nurse at the RMIT University Health Service using standard vacutainer collection tubes. Blood for lipid analysis and cell counts was collected into EDTA containing vacutainers (Greiner Labortechnik, Austria). Blood for platelet fatty acid analysis was collected into CTAD (citric acid, theophylline, adenosine, dipyridamole) vacutainers (Becton Dickinson Ltd, Cowley, UK). Blood for whole blood platelet aggregation and the coagulation and ®brinolytic factors was collected into separate sodium citrate vacutainers (Greiner Labortechnik). EDTA and citrated plasma were obtained from blood spun at 3000 rpm at 4 C for 15 min. Plasma phospholipid (PL) fatty acids, total cholesterol, HDL cholesterol and triacylglycerols were determined from EDTA plasma stored at À20 C. Citrated plasma was stored at À70 C for subsequent analysis of coagulation and ®brinolytic factors. Following blood collection, CTAD tubes were maintained at 37 C to prevent platelet activation and used within 1 h for platelet aggregation by the method of Castaldi and Smith (1980) .
Plasma lipoprotein lipids
Total cholesterol (TC) and triacylglycerol (TAG) concentrations in plasma were determined with a centrifugal autoanalyser (Hitachi Autoanalyser System 705, Japan) using commercially available enzymatic kits, CHOD-PAP and GPO-PAP for TC and TAG, respectively (Boehringer Mannheim, Germany). High-density lipoprotein cholesterol (HDL-C) was measured after all other plasma lipoproteins were precipitated with polyethylene glycol 6000 (PEG-6000, BDH Chemicals, Kilsyth, Victoria). Low density lipoprotein cholesterol (LDL-C) was calculated from the values obtained for TC, HDL-C and TAG for each subject by using the Friedewald formula as developed by DeLong et al (1986) .
Platelet and plasma fatty acids
Platelet and plasma lipids were extracted with chloroform: methanol 1:1 (C:M, vav) containing 10 mgal of butylated hydroxytoluene (Labco, Vic, Australia), and 10 mgal of C17:0 phospholipid (La-phosphatidylcholine diheptadecanoyl, Sigma-Aldrich, Pty. Limited, NSW, Australia) as internal standard, as reported previously (Sinclair et al, 1987) . The total platelet PL and total plasma PL fractions were separated by thin-layer chromatography. The methyl esters of the fatty acids were prepared by saponi®cation using KOH (0.68 molal in methanol) followed by transesteri®cation with 20% boron tri¯uoride (BF 3 ) in methanol and the fatty acid compositions were determined by gas ± liquid chromatography as previously described (Sinclair et al, 1987) .
Full blood examination
A full blood cell count (including platelet count (Plt) and mean platelet volume (MPV)) was performed on an automated haematological analyser (Coulter Counter STKR, Coulter Electronics Inc., Hialeah, USA) within 2 h of blood collection.
Plasma haemostatic factors
Prothrombin time (PT), activated partial thromboplastin time (APTT), ®brinogen, factor VII coagulant activity (FVII:C), plasminogen and antithrombin III (ATIII) levels were determined using a centrifugal analyser (ACL 200, Coulter IL, Ltd) with commercially available kits (Coulter, Instrumentation Laboratory, Milano, Italy).
Agonist induced ex vivo whole blood platelet aggregation Platelet aggregation was determined in whole blood using a two-channel whole blood impedance aggregometer (Chrono-Log Aggregometer, Model 540V5, Chrono-Log Corporation, Havertown, Philadelphia, USA). Agonists used were collagen (2 mgal), arachidonic acid (AA, 1.0 mmolal) and adenosine diphosphate (ADP) (8 and 17 mmolal). Aggregation was measured as rate of aggregation (slope, Oamin) as reported by Ingerman-Wojenski and Silver (1984) .
Statistical analyses
Statistical analysis was performed using Statistical Packages for Social Scientists (SPSS version 9.0, 1998, Chicago, IL) . Comparisons between the dietary groups involved a threeway repeated measures analysis of variance using a general linear model (GLM), where diet type (palmitic or stearic rich) and time were within-subject factors and dietary order was the between-subject factor (P`0.05 was regarded as signi®cant). Comparisons within individual diets (between days 0 and 28) were conducted on parameters where a signi®cant time Â treatment interaction or time effect was observed using paired t-tests and Bonferroni correction (P`0.025 was regarded as signi®cant). Stearic acid-rich diet FD Kelly et al
Results
All subjects stayed within 2 kg of their initial body weights throughout the dietary phases of the study. There were no signi®cant changes in BMI, waist-to-hip ratio, or blood pressure during either dietary period. The mean nutrient intakes for all subjects at baseline and during the two dietary phases are presented in Table 2 . There were no signi®cant differences in total energy intake during either dietary period compared with baseline or between the two dietary phases. The changes in the percentage of total energy (%TE) of protein, fat and carbohydrate during diet S were not signi®cantly different to those during diet P. There was a signi®cant decrease in fat intake (%TE, P`0.025) compared with baseline during diet P. Compared with baseline, there was a signi®cant decrease (P`0.025) in the percentage of total energy (%TE) from saturated and polyunsaturated fatty acids (PUFA) during diet S and a signi®cant decrease (P`0.025) in PUFA during diet P. Compared with their respective baseline intakes, there was a signi®cant increase (P`0.025) in MUFA (%TE) during both diet S and diet P.
There was a 12gaday increase in stearic acid (P`0.025) and a 9 gaday decrease (P`0.025) in palmitic acid intake on diet S. On diet P, there was a 7 gaday increase (P`0.025) in palmitic acid and a Table 2 Daily nutrient intakes of subjects at baseline (habitual diet) and during the 4 week stearic acid (diet S) and palmitic acid (diet P) intervention periods (n 13) 3 gaday decrease (P`0.025) in stearic acid. The changes in the amount of stearic, palmitic and oleic acid intake on diet S were signi®cantly different (P`0.05) to those on diet P. On both diets there were signi®cant changes (relative to baseline) for other fatty acids, particularly an increase in oleic acid and decrease in linoleic acid (Table  3) . While these changes were not planned, they were the result of efforts to maintain energy intake constant while removing certain fat sources from the diet and replacing them with the test fats. The results of lipoprotein concentrations are reported in Table 4 . Diet S resulted in a signi®cant decrease in totalcholesterol (TC), HDL-cholesterol (HDL-C) and LDLcholesterol (LDL-C, P`0.025) compared with baseline, however, there were no signi®cant changes in plasma lipoprotein lipids on diet P. A diet order effect was present in the changes in TC and HDL-C (ie affected by whether the subjects started on diet S or diet P ®rst). TC and HDL-C fell in both groups on diet P but fell signi®cantly more in one group than the other on diet S.
The full blood examination and haemostatic parameters are reported in Table 5 . There was a signi®cant difference (P`0.05) in the change in MPV on diet S compared with diet P. The MPV decreased signi®cantly following diet S (P`0.025) while there was no change in MPV on diet P. The diet order effect on diet P was due to one group showing an increased MPV value. The FVII:C activity was signi®cantly decreased (P`0.025) during diet S compared with baseline. The FVII:C activity and ®brinogen levels of two samples taken during diet S were excluded from calculations due to suspected pre-activation of clotting (related to venipuncture technique). There were no signi®-cant changes in PT, APTT, plasminogen, ®brinogen or ATIII on either diet.
Fatty acid compositions of platelet PL are shown in Table  6 . There were signi®cant differences in the changes in platelet stearic and palmitic acid levels on diet S compared with diet P (P`0.05). Diet S resulted in signi®cantly increased stearic-acid levels and signi®cantly decreased palmitic acid levels in platelet PL compared with baseline Table 4 Lipoprotein concentration of subjects at baseline (habitual diet) and during the 4 week stearic acid (diet S) and palmitic acid (diet P) intervention periods (n 13) Table 5 Full blood examination and haematological parameters of subjects at baseline and the end of the 4 week stearic acid (diet S) and palmitic acid (diet P) intervention periods (n 13) c P, level of signi®cance; T, signi®cant time effect, P`0.05; T Â D, signi®cantly different change in parameter between diets, P`0.05 (time Â treatment interaction); GLM Ð repeated measures ANOVA. *Signi®cantly different from baseline within diet, P`0.025 (paired t-test Bonferroni correction), applied to parameters where a signi®cant time Â treatment interaction or time effect was observed.
{
Signi®cant dietary order effect, P`0.05 (GLM Ð repeated measures ANOVA).
Stearic acid-rich diet FD Kelly et al (P`0.025). Diet P resulted in a signi®cant increase (P`0.025) in the palmitic acid level in platelet PL. These changes were of a lesser magnitude compared with the change on diet S. Both dietary interventions resulted in a signi®cant decrease in linoleic acid and a signi®cant increase in oleic acid (P`0.025) compared with baseline. On diet S there was a signi®cant increase (P`0.025) in the stearic acid proportion in the plasma PL (13.6 AE 1.2% to 16.5 AE 2.3% of plasma PL fatty acids) and a signi®cant decrease (P`0.025) in the level of palmitic acid (28.1 AE 1.7% to 25.9 AE 2.4%). Diet P led to a signi®cant increase (P`0.025) in the level of palmitic acid (28.3 AE 1.7% to 29.9 AE 1.2%). The changes in the proportion of stearic acid and palmitic acids on diet S were signi®cantly different (P`0.05) to those on diet P (data not shown).
Agonist-induced whole blood platelet aggregation results are reported in Table 7 . On diet S, there were no signi®cant changes in the rate of aggregation while during diet P, the rate of aggregation was signi®cantly increased (P`0.025) in response to collagen and ADP (8 and 17 mm) compared to baseline.
Discussion
This study examined the effect of diets rich in stearic acid relative to palmitic acid on thrombotic risk factors associated with platelets and haemostasis, with platelet aggregation as an important outcome. The test fats were prepared by interesterifying blends of particular fats as described, which Table 7 Agonist-induced whole blood platelet aggregation in subjects at baseline and the end of the 4 week stearic acid (diet S) and palmitic acid (diet P) intervention periods c n 12. d P, level of signi®cance; T, signi®cant time effect, P`0.05; T Â D, signi®cantly different change in dietary intake between diets, P`0.05 (time Â treatment interaction); GLM Ð repeated measures ANOVA. *Signi®cantly different from baseline within diet, P`0.025 (paired t-test Bonferroni correction), applied to parameters where a signi®cant time Â treatment interaction or time effect was observed. Table 6 Fatty acid composition of total platelet phospholipids (percentage fatty acid) of subjects at baseline and the end of the 4 week stearic acid (diet S) and palmitic acid (diet P) intervention periods (n 13) gave stearic acid or palmitic acid-rich products; however, in order to make the stearic products spreadable, the stearic acid products contained a higher level of oleic acid than the palmitic acid products. Thus, it is conceivable that some of the results found could be in¯uenced by the stearic acid content as well as the oleic acid content. In reality, the oleic acid intakeadayasubject on the stearic acid diet was 37 gaday compared with 33 gaday on the palmitic acid diet and the difference was probably not of biological signi®cance. We do not know of any evidence which shows that this small difference in oleic acid between the two diets would produce the changes in platelet aggregation, MPV or Factor VII observed. There were no effects of diet S on collagen or ADP agonist-induced in vitro platelet aggregation, despite the fact that the stearic acid level in platelets increased signi®cantly (P`0.025). In contrast, diet P led to a signi®cant increase in the level of palmitic acid in the platelets which was associated with a signi®cant increase in agonistinduced platelet aggregation in response to collagen and ADP. This ®nding is novel since no previous studies have compared platelet aggregation on diets rich in stearic acid vs palmitic acid.
In vitro platelet aggregation is based on the assumption that an increased response indicates an increased tendency for thrombogenesis in vivo. Interpretation of results, however, is dif®cult due to many factors affecting in vitro measurements (Schoene, 1997) . To date, the data reported by various authors on the effect of dietary stearic acid on platelet aggregation are con¯icting. It has been demonstrated that, for a particular dietary fatty acid, the aggregatory response to the same agonist can give opposing results (Turpeinen et al, 1998; Kwon et al, 1991) , due partly to the medium in which platelets have been assessed. There is argument as to whether whole blood or platelet-rich plasma (PRP) samples are more appropriate for determination of ex vivo aggregation, or as a model to represent the in vivo situation. Whole blood aggregation testing used in the present study may represent more closely physiological in vivo conditions compared with PRP used in other studies (Renaud et al, 1981; 1986a, b) . It has been demonstrated, using whole blood in vitro aggregation techniques, that platelet aggregates contain both leukocytes and erythrocytes (Joseph et al, 1989) . Leukocytes can down-regulate platelet reactivity via prostacyclin synthesis while erythrocytes can enhance platelet activation via ADP release, the active takeup of adenine nucleotides and the preferential binding of prostacylin. These factors which can in¯uence platelet function are excluded in the process of aggregation in PRP as opposed to whole blood techniques which allow the study of platelets in their natural milieu (Joseph et al, 1989; Marcus & Sa®er, 1993; Homstra, 1989) . Despite this, some researchers still believe that PRP is more appropriate since it removes such factors giving a better picture of the changes in platelets (Turpeinen et al, 1998) . Turpeinen et al (1998) demonstrated using PRP that a high stearic acid containing diet (9.3% total energy) for 5 weeks in a group of 80 volunteers led to a signi®cantly enhanced collagen-induced platelet aggregation (but not with ADP) compared with a high trans fatty acid diet (8.7% total energy). In comparison, a study by Kwon et al (1991) incorporating a 3 week controlled SFA diet, demonstrated using whole blood that stearic acid in platelet phospholipids was associated (r À0.69) with decreased collagen-induced platelet aggregation, suggesting that stearic acid may not be prothrombotic. Tholstrup et al (1996) studied the acute effects of stearic and myristic acids on ADP-and collagen-induced platelet aggregation. Both diets reduced platelet aggregation postprandially after a high-fat meal compared with fasting levels, with signi®cantly lower platelet aggregation at 24 h after consumption of stearic acid than myristic acid. It was hypothesized that a mechanism for this decrease in aggregation was the coating of the platelets with chylomicrons, which may interfere with the platelet ± collagen interaction in the initial stage of platelet aggregation (platelet activation).
In the present study, MPV signi®cantly decreased on diet S by 6% relative to baseline and by 7% relative to diet P. This ®nding is supported by data from Schoene et al (1992) , who reported a similar decrease in MPV in 10 subjects fed in excess of 20 g stearic acidaday from shea butter compared with a high palmitic acid diet. The MPV is regarded as an index of platelet activation and has been shown to be an independent risk factor for recurrent myocardial infarction (Martin et al, 1991; Schultheiss et al, 1994) . Platelets normally circulate as thin discs and smaller platelets are thought to be less active and, thus, in a quiescent state are less likely to be involved in thrombotic conditions (Schoene et al, 1992) . Activated platelets produce changes in the platelet microtubules, causing them to undergo a disc-tosphere shape transformation (Laufer et al, 1979) , resulting in an increase in volume, and these larger platelets have been shown to have enhanced activity (Abbate & Boddi, 1987; Sharp et al, 1994) . Flow cytometry techniques have demonstrated that this greater reactivity of larger platelets is associated with more ®brinogen receptors being exposed, initiating arterial thrombi formation to a greater extent than smaller platelets (Giles et al, 1994; Michelson, 1996) . Further studies on the biological signi®cance in the reduction of the MPV following stearic acid-rich diets are warranted.
Prospective studies have demonstrated that coagulation factor VII is an independent predictor of total and fatal CHD in the ®rst 5 y of follow up of the Northwick Park Heart Study (NPHS) (Meade et al, 1980 (Meade et al, , 1986 . This observation has also been found in fatal CHD in longer follow-up periods of the NPHS (Meade et al, 1993) and The Prospective Cardiovascular Munster (PROCAM) study (Assmann et al, 1996) . It has also been suggested that decreasing the total dietary fat content reduces factor VII coagulant activity (Marckmann et al, 1990 (Marckmann et al, , 1993 Miller et al, 1989) . FVII:C signi®cantly decreased on diet S relative to baseline, suggesting favourable effects on haemostasis while no signi®cant change was observed on diet P. Tholstrup et al, (1994) also observed a 13% decrease in factor VII on a stearic acid-rich diet (from shea butter) compared with a high palmitic acid diet. In contrast, Mutanen & Aro (1997) demonstrated no signi®cant difference in the level of FVII:C in 40 subjects fed stearic acid-rich diets (9.3% total energy) for 5 weeks. Some authors have suggested that shea fat has a unique ability in lowering FVII:C which may be unrelated to its fatty acid composition, but more related to the nonglyceride components such as tocopherols and hydrocarbons (Tholstrup et al, 1994; Mutanen & Aro, 1997) .
Total cholesterol, LDL-C and HDL-C levels in the plasma were all signi®cantly decreased on diet S. The total cholesterol and LDL-C results observed are consistent with data from Bonanome and Grundy (1988) , Tholstrup et al (1994) and Dougherty et al (1995) , while signi®cant decreases in HDL-C concentrations on high stearic acid diets compared with baseline have been previously reported by Tholstrup et al (1994) and Dougherty et al (1995) . The lack of effect on the plasma TAG concentration is consistent with other data on stearic acid rich diets (Tholstrup et al, 1994; Dougherty et al, 1995; Bonanome & Grundy, 1988) . The mechanisms by which stearic acid lower plasma cholesterol levels are still uncertain; however, they may in part be due to the regio-speci®c location of the saturated fatty acids, which in turn in¯uences their absorption and further metabolism. These properties have been attributed, ®rstly, to the lower gastrointestinal absorption rates of stearate, especially when found in the sn-1 and sn-3 positions of the triacylglycerol (Kritchevsky, 1994; Bracco, 1994) . This is largely due to its melting point being above body temperature and its ability to form calcium soaps (Small, 1991) . Secondly, it is possible that stearic acid is rapidly converted to oleic acid in the liver (Grundy, 1994) , thus reducing its potential impact on saturated fatty acid levels in the body. In natural lipid sources such as cocoa butter and shea butter (Dougherty et al, 1995) , the stearic acid is predominantly located in the sn-1 and sn-3 positions with minimal amounts in the sn-2 position (Padley et al, 1994) . However, when fats are interesteri®ed, as with the fats used in the present study, a greater proportion of stearic acid is located in the sn-2 position, which is absorbed into the mucosal cells as a monoacylglycerol. Further studies to show the absorption of stearic acid from the sn-2 position could include chylomicron studies postprandially after stearic feeding and also faecal studies to determine apparent absorption of these formulated fats.
The use of stearic acid-rich lipid sources could be of advantage to the food industry if it displaces other saturated and trans fatty acids from the foods, giving them nutritional and physiological advantages over natural lipid sources. Furthermore, if the stearic acid-rich lipid source is interesteri®ed, a greater proportion of stearic acid could be randomly distributed to the sn-2 position which in turn could increase the amounts absorbed compared with natural lipid sources.
In this study, the platelet stearic acid level increased by 22% on diet S, which is consistent with the extent of increase reported by Turpeinen et al (1998) . Plasma phospholipid stearic acid levels also increased by 21% in the present study. It has been shown there is a high proportion of stearic acid in platelet phosphatidylserine and phosphatidylinositol, which are important phospholipids for cell membrane signalling events (Mori et al, 1987) . Perhaps the increased stearic acid in the platelet membranes is speci®c for one of these two phospholipids or alternatively the increased stearic acid might in¯uence the function of cell membrane receptors through changes in membranē uidity (Litman & Mitchell, 1996) . This study supports other studies which show that diets enriched in stearic acid do not contribute to an increase in classical cardiovascular risk factors and those related to thrombosis. These data might appear to be in contradiction with the recent report by Hu et al (1999) , who suggest that there is no basis for a distinction between stearic acid and other saturated fatty acids in`normal' diets, because of the high correlation between these two factors. Since stearic acid levels in`normal' diets are half those of palmitic plus myristic acid levels, it is not a major saturated fatty acid in our diet. Our data on a modi®ed diet, containing approximately 2.5 times more stearic acid than usual, raises the possibility of using an increased amount of stearic acid in the food supply in place of those fats rich in palmitic and myristic acids or trans fatty acids. The stearic acid could satisfy the requirements for particular physical properties in the food while appearing to have either neutral or bene®cial effects in relation to risk factors for cardiovascular disease.
